Back to search

Ireland· IE-PA-EU/1/22/1638/003-004

QUVIVIQ 50 mg film-coated tablets

A daridorexant product containing daridorexant hydrochloride, registered in Ireland by Idorsia Pharmaceuticals Deutschland GmbH. The same ATC class is registered in 15 of our 19 countries.

ATC N05CJ03

Checked against HPRA (Ireland) on

Informational only — not a medical device.

SOURCE REGISTER · IEHPRA (Ireland)normalisedQUVIVIQ 50 mg film-coated tabletsATCN05CJ03REGISTER NO.IE-PA-EU/1/22/1638/00…PACKS LISTED1CHECKEDSeptember 28, 2026

Where it is registered

Daridorexant is registered in 15 of 19 countries.

Countries holding a registration under ATC N05CJ03 (daridorexant), each read from that country’s own register.

  • This record: Ireland, from HPRA (Ireland)
  • 10 of them publish a price we can compare per daily dose

Daridorexant · ATC N05CJ03

15 / 19 countries

  • Belgiumprice
  • Canada
  • Czechiaprice
  • Denmark
  • Finlandprice
  • Franceprice
  • Icelandprice
  • Ireland
  • Netherlands
  • Norwayprice
  • Polandprice
  • Spainprice
  • Switzerlandprice
  • United Kingdom
  • United Statesprice
Blue: a registration under this ATC code. The ringed marker is this record’s country. Markets marked price publish a price we can compare per daily dose.

Price per daily dose

What a daily dose of daridorexant costs, country by country.

Normalised to the WHO defined daily dose (50 mg), so markets compare like for like.

  • 1 market with a comparable price for this class
  • Public list prices, converted to USD at the rate date shown

Daridorexant · price per daily dose (50 mg)

USD · FX 28 Sept 2026

  • FR France$3.24
Median listed price per WHO defined daily dose, in each market that publishes a price. Open the full comparison

The record

At a glance

HPRA (Ireland)
Active substance
Daridorexant hydrochloride
Manufacturer
Idorsia Pharmaceuticals Deutschland GmbH
Country
Ireland (IE)
ATC code
N05CJ03
ATC class
Daridorexant
Defined daily dose
50 mg, O
Reimbursed
Not published by this register
Source register
HPRA (Ireland)
Last checked
September 28, 2026

Packs & prices · 1

  • ie_pa_number
    EU/1/22/1638/003-004

Regulatory notes

No shortage, Orange Book or US label notes for this record.

Same medicine, other countries

Daridorexant in 14 other countries

What each register calls a product with the same active substance — salts and hydrates count as the same.

All daridorexant products

Authorised across Europe · EMA

The same active substance is authorised in 3 EEA countries. Names it is sold under:

  • Iceland · Quviviq
  • Liechtenstein · Quviviq
  • Norway · Quviviq

Source: European Medicines Agency, Article 57 product data.

Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of HPRA (Ireland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.

For developers

The same record over the API, and the raw payload
GET /v1/drugs/2b37bcf3-ed62-4d33-a1aa-72bf6018d0a1
GET /v1/drugs/2b37bcf3-ed62-4d33-a1aa-72bf6018d0a1?format=fhir

Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.

{
  "form": "Film-coated tablet",
  "routes": [
    "Oral use"
  ],
  "source": "hpra",
  "atc_all": [
    "N05CJ03"
  ],
  "strength": null,
  "pa_number": "EU/1/22/1638/003-004",
  "substances": [
    "Daridorexant hydrochloride"
  ],
  "legal_basis": "Full application (Article 8(3) of Directive No 2001/83/EC)",
  "market_info": "Unknown",
  "authorised_at": "29/04/2022",
  "dispensing_status": "Product subject to prescription which may not be renewed (A)",
  "registration_status": "AU",
  "supply_legal_status": "Supply through pharmacies only",
  "interchangeable_code": null
}

See everything about daridorexant.

This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.